Omnicare Inc

Omnicare — Q2 2012 Earnings Presentation

18 slides from Omnicare's earnings presentation, Jul 25, 2012

  1. Slide 1: Second Quarter 2012 Financial Results

  2. Slide 2: Forward-Looking Statements

    Forward-Look Statements Cc i of the Pri lies Litigation Reform Act of 1995. These forwarcHooking ‘statements. indude, but all statements ‘or current expectations presentation. k id unknown risks, uncertainties, conti differ materially The most significant of Company's Form 10-K, Form 10-Q and Form 8

  3. Slide 3: Table of Contents

    Table of Contents Second Quarter 2012 Highlights... Operating Metrics — Script Data... Operating Metrics — Long-Term Care Bed Data... Gross Profit & Adjusted Operating Income Adjusted Net Income & Cash-based EPS. . Adjusted Operating Income by Segment .. Cash Flows. Cash Deployment.. Capital Structu

  4. Slide 4: Second Quarter 2012 Highlights

    Second Quarter 2012 Highlights Gross profit 9.2% higher year-over-year to $367.3M on 230 bps margin increase Adjusted EBITDA")® increased 16.4% year-over-year to $170.3M Adjusted Cash-Based EPS") of $0.83; 20.3% increase over $0.69 in 2Q11 Long-Term Care Group second-quarter performance: — Netsales

  5. Slide 5: Operating Metrics: Script Data

    Operating Metrics Script Data Sequential Prior Year Increase / Increase / (In thousands, except %s) 2Q 2012 102012 (Decrease) _2Q 2011 (Decrease) Long-Term Care Group Scripts: Generic scripts dispensed 20,528 20,361 0.8% 19,529 5.1% Branded scripts dispensed 4372 5,083 (14.0%) 5,506 (20.6%) Over-the

  6. Slide 6: Operating Metrics: Long-Term Care Bed Data

    Operating Metrics Long-Term Care Bed Data Sequential Prior Year Increase / Increase / (In thousands) 2Q2012 102012 (Decrease) 202011 (Decrease) Beds served: Beginning of period - LTC Beds 986 1,010 (24) 1,014 (28) Net change in beds served 9) (24) 15 1 End of period - LTC Beds 977 986 9) 1,003 (26)

  7. Slide 7: Gross Profit & Adjusted Operating Income

    Gross Profit & Adjusted Operating Income ()) Sequential Prior Year Increase / Increase / In millions, except per share data and %s 2Q 2012 1Q 2012 (Decrease) 2Q 2011 (Decrease) Net sales $ 1,586.0 $ 1,593.1 (8.6%) “$ 1,555.9 (1.3%) Cost of sales Gross profit Rate BObps 21.62% 229 bps SG&A expenses 2

  8. Slide 8: Adjusted Net Income & Cash-based EPS

    Adjusted Net Income & Cash-based EPS")() Sequential Prior Year Increase / Increase / In millions, except per share data and %s 22012 12012 (Decrease) _2Q2011__ (Decrease) ‘Adjusted operating income $ 141.4 § 143.5 (1.5%) “$119.6 18.2% ‘Adjusted interest expense, net Sesion income (25.6) (24.5) 4.5%

  9. Slide 9: Adjusted Operating Income by Segment

    Adjusted Operating Income by Segment “) Sequential Prior Year Increase / Increase / In millions, except %s 202012 _ 102012 _(Decrease| 20.2011 (Decrease Long-Term Care Group t sales $ 1,202.8 $ 1,296.3 (7.2%) $ 1,289.4 (6.7%) Adjusted operating income from continuing operations 150.8 154.2 (2.2%) 12

  10. Slide 10: Cash Flows

    Cash Flows (1) Sequential Prior Year Increase / Increase / In Mate except %s 2Q 2012 1Q2012 (Decrease) 2Q 2011 (Decrease) a in $ (66.4%) $ ig ) 1435.7% Los: mis ‘continued operati : : : (100.0%) pausinetis i reconcile at wean to net cash flows from operating ivi “Dep reciation expense 12.4 124 2.5%

  11. Slide 11: Cash Deployment

    Cash Deployment In millions, except %s 20 2012 conti operations (reported) $ 1202 Capital oenctures 262 Acquisition: - Net debt od Jong term borrowings repayment “”) 30.7 Capital returned: Dividends paid $ 77 Share repurchases 58.0 Total capital return: 657 % of net cash fos from operating activitie

  12. Slide 12: Capital Structure

    Capital Structure Major Debt Maturity Schedule” (in $ millions) $1,800 As of 9/30/10 $1,500 | As of 6/30/12, —— $1,200 $900 $600

  13. Slide 13: 2012 Guidance

    2012 Guidance Po Previous Guidance “) | Current Guidance @ - Revenue $6.1B to $6.2B $6.1B to $6.2B - Adjusted cash earnings per diluted share) $3.10 to $3.20 $3.22 to $3.28 * Cash flow from operations“) $400M to $500M $425M to $525M

  14. Slide 14: Longer-Term Targets

    Longer-Term Targets “) a + Adjusted cash earnings per diluted share High single-digit CAGR for the from continuing operations two years ending 2013 + Cash flow from operations $400-$500 million annually + Capital returned to shareholders Approximately 25% per year) Continued debt reduction, manageme

  15. Slide 15: Appendix

  16. Slide 16: Working Capital Management

    Working Capital Management Five Quarter Trend 40 75 a a ves we 26.7 275 20 63 10 16.8. oF 55.0. 56.7 $5.2

  17. Slide 17: Selected Branded Drug Patent Expirations

    Selected Branded Drug Patent Expirations).@) 2Q 2012 Lescol IR Lovenox Vials Plavix Provigil Requip XR Stalevo Vancocin Caps Viramune 3Q-4Q 2012 Actos Comtan Detrol IR Diovan IR Diovan HCT Fosrenol Mucinex Revatio Singulair Xopenex Ziagen FY 2013 Aciphex Asacol Cymbalta Fragmin Lidoderm Lunesta Nias

  18. Slide 18: Second Quarter 2012 Financial Results

Omnicare — Q2 2012 Earnings Presentation on 6ix